Medidata Consent, a key part of the Medidata Patient Experience, expedites study start-up, reduces configuration complexity, and improves patient enrollment New York – Oct. 30, 2025 – Medidata, a ...
Former Inizio Evoke President of CX joins Supreme Group’s management team to lead platform-wide growth strategy WEST CHESTER, Pa. — Oct. 30, 2025 — Supreme Group, a next-generation agency platform ...
Physician-led wellness brand brings its evidence-based longevity and recovery model to downtown LA. LOS ANGELES, CA / ACCESS ...
AGFA HealthCare will highlight what truly drives transformation in medical imaging: clinicians. CARLSTADT, NEW JERSEY / ACCESS Newswire / October 30, 2025 / While technology enables progress, AGFA ...
MESA, ARIZONA / ACCESS Newswire / October 30, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a diversified holding company operating at the intersection of technology, wellness, and ...
NEW YORK, NY / ACCESS Newswire / October 30, 2025 / In the face of growing global concern over the potential use of chemical weapons such as the nerve agent Sarin, Lunai Bioworks Inc. (NASDAQ:LNAI) ...
BOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics (NASDAQ:ENTO) has just made one of the boldest moves in its history, a reinvention that trades long biotech timelines for ...
Boehringer Ingelheim licences a novel small-molecule treatment from Kyowa Kirin for fibro-inflammatory and autoimmune diseases in a deal worth up to €410 million.
Novo Nordisk has topped Pfizer’s offer for Metsera with a bid of up to US$9 billion, seeking to secure Metsera’s obesity-drug ...
Regeneron and ModeX Therapeutics have joined forces in a collaboration worth over one billion dollars to develop ...
CNX Therapeutics, a specialty pharmaceutical company, has been recognised with two prestigious industry awards during CPHI week in Frankfurt, marking three awards in two months for the London-based ...
Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation. First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback